Pfizer has finalized a deal to acquire U.S. obesity-drug biotech Metsera for up to $10 billion, outbidding Novo Nordisk in a heated contest.
The agreement offers $65.60 per share in cash plus a contingent value right worth up to $20.65, delivering immediate value to Metsera’s shareholders.
The deal follows the Federal Trade Commission (FTC) warnings that Novo Nordisk’s rival offer posed significant antitrust risks due to its structure, which could have bypassed standard merger reviews. Metsera cited these regulatory concerns as the reason for accepting Pfizer’s revised terms.
The acquisition strengthens Pfizer’s position in the fast-growing obesity treatment market, where Metsera’s pipeline includes promising GLP-1 and amylin-based therapies with potential for monthly dosing.
The transaction is expected to close after a shareholder vote on November 13, 2025.
Administrator and Writer
